Columbia University Medical Center has launched the first clinical trial of a possible herbal preventative for prostate cancer.The phase I study will determine whether Zyflamend, a herbal supplement commonly used as an anti-inflammatory, can prevent prostate cancer in patients with prostatic intraepithelial neoplasia (PIN). PIN - meaning that the top layer of cells or epithelial cells of the prostate are dividing more rapidly than normal epithelial cells - is a clinical precursor for prostate cancer.Without intervention, men diagnosed with PIN have a 50 to 70 per cent likelihood of developing prostate cancer.
